anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: An accelerated diagnostic pathway is created to aid the management of low-risk patients presenting to the emergency room with chest pain. Records are taken of patient outcomes and factors influencing physician decision-making between inpatient invasive angiography versus early outpatient cardiac CT angiography.
METHODS: A cohort study at 30 days post discharge is undertaken over 1 year. Differences are observed between a population of patients who underwent early outpatient CT and a population of ambulatory haemodynamically stable patients who underwent inpatient fluoroscopic angiography.
RESULTS: Totally, 369 patients underwent CT (F = 46%) and 37 underwent angiography (F = 30%). Median outpatient CT was at 14 days. At 30 days, 0 patients suffered mortality or myocardial infarction. Eleven percent were recommended for invasive angiography. Two percent of CT patients underwent coronary revascularization. Median calcium score was 0. Twenty percent of the CT population were commenced on high-potency statin or had their pre-existing statin dose intensified. Calcium score affected a composition of statin commencement, angiography, and revascularization (OR 59, P < .001). Age, troponin, vascular disease, and previous coronary revascularization appeared to influence choice between coronary computed tomography angiography (CCTA) and invasive angiography.
CONCLUSION: An accelerated diagnostic pathway for outpatient cardiac CT for chest pain resulted in no mortality or myocardial infarction, with a low level of downstream testing and coronary revascularization.
ADVANCES IN KNOWLEDGE: At a median time to CCTA of 14 days post discharge from the emergency department, there is no effect on patient major adverse cardiac events.
In patients already scheduled to undergo sentinel lymph node dissection in the operating room, the investigators will first perform an axillary ultrasound guided core needle biopsy percutaneously. Patients will have already undergone prior injection of radioisotope and blue dye and as a standard procedure or the sentinel lymph node dissection. After induction of anesthesia, the investigators will identify the location of the sentinel node with a gamma probe to identify the "pre-incision hot spot." Axillary ultrasound will then be used to identify the location of the lymph node and a percutaneous core needle biopsy of the targeted lymph node will be performed. The core biopsy specimen will be evaluated for the presence of blue staining and radioisotope uptake intraoperatively. The core biopsy specimen will then will be sent for pathologic analysis. The percutaneous biopsy should take about 10 minutes of additional operating room time. The operation will then proceed as planned with dissection and removal of the remaining sentinel node(s). Core samples and sentinel lymph nodes will be evaluated in a similar fashion per existing sentinel node protocol.
The invention discloses a group of substances for inducing mesenchymal stem cells to differentiate towards brown fat. The material comprises cinnamaldehyde and glycyrrhetinic acid and a composition of the cinnamaldehyde and the glycyrrhetinic acid in different proportions. Wherein the ratio of the composition is 1:1, and the concentration of the two components is 20 mu mol.L in the culture medium  ‑1  The effect of the composition is optimal. Compared with the prior art, the cinnamon used in the inventionThe aldehyde and the glycyrrhetinic acid are all pure natural substances, so that the medicine is safe and has no toxic or side effect. Is expected to provide a safer and more reliable therapeutic drug or health-care product for treating or preventing obesity, hyperlipidemia, metabolic syndrome and other related diseases. Meanwhile, the preparation method can also be used as a reagent for inducing the mesenchymal stem cells to differentiate into brown adipocytes and preparing the brown adipocytes.
The case report by Dwyre et al. shows that vitamin B12 deficiency may be misdiagnosed as acute thrombotic thrombocytopenic purpura. Together with similar observations, this underlines that acquired vitamin B12 deficiency-besides the inherited disorder of intracellular cobalamin metabolism, cbl C disease-should be listed as a separate entity of the thrombotic microangiopathies. Commentary on: Dwyre et al. Microangiopathic thrombocytopenia caused by vitamin B12 deficiency responding to plasma exchange. Br J Haematol 2024; 205:1546-1550.
Chronic obstructive pulmonary disease (COPD) is India's second largest cause of death and is largely caused by smoking. Asymptomatic smokers develop COPD due to genetic, environmental, and molecular variables, making early screening crucial. Data-independent acquisition mass spectrometry (DIA-MS) based-proteomics offers an unbiased method to analyze proteomic profiles. This study is the first to use DIA-based proteomics to analyze individual serum samples from three distinct male cohorts: healthy individuals (n = 10), asymptomatic smokers (n = 10), and COPD patients (n = 10). This comprehensive approach identified 667 proteins with a 1% false discovery rate. Differentially expressed proteins included 40 in the normal versus asymptomatic comparison, 88 in the COPD versus normal comparison, and 40 in the COPD versus asymptomatic comparison. Among them, protein-associated genes such as PRDX6, ELANE, PRKCSH, PRTN3, and MNDA could help differentiate COPD from asymptomatic smokers, while ELANE, H3-3A, IGHE, SLC4A1, and SERPINA11 could differentiate COPD from healthy subjects. Pathway enrichment and protein-protein interaction analyses revealed significant alterations in hemostasis, immune system functions, fibrin clot formation, and post-translational protein modifications. Key proteins were validated using a parallel reaction monitoring assay. DIA data are available via ProteomeXchange with identifier PXD055242. Our findings reveal key protein classifiers in COPD patients, asymptomatic smokers, and healthy individuals, helping clinicians understand disease pathobiology and improve disease management and quality of life.
Pilot Study, Randomized Control Clinical Trial, study groups 1) Craniofacial and/or unilateral and bilateral cleft palate patients undergoing orthognathic surgery . 2) Craniofacial and/or unilateral and bilateral cleft palate patients undergoing bone-graft surgery 3) Craniofacial and/or unilateral and bilateral cleft palate patients with no pending surgery. Three Investigational device include Dual Light Therapy Sonic Toothbrush (BristlTM Toothbrush), Sonic Toothbrush(BRistlTM) and manual toothbrush to target disease gingivitis in 189 patients. Categorical variables scored from Plaque Index and Gingival Index will be analyzed using Fisher exact test and McNemar test. Parametric methods will be used to analyze data from Bleeding on Probing and Periodontal Probing Depth. To determine differences between groups and within each test at all time points, Student t-test will be used.
Intravenous infusion of levcromakalim (1 mg/20 ml). The infusion is administered at constant speed by an automatic pump, lasting 20 minutes.
A patient data exchange system comprises at least one device. Each of the devices implements an interface. When a device in the patient data exchange system publishes patient data, the device generates a metadata envelope that encapsulates the patient data. The metadata envelope conforms to a schema that defines allowable metadata attributes of the metadata envelope. When a device in the patient data exchange system receives a metadata envelope that conforms to the schema, the device determines, based at least in part on a metadata attribute of the metadata envelope, a particular patient data handling policy to apply to patient data encapsulated by the metadata envelope. In some instances, the metadata attribute indicates that authorization is required from an authorization service to access the patient data encapsulated by the metadata envelope.
Described herein are inventive compositions and methods relating to polymer conjugates and, in particular, to polymer conjugates having pendant side groups comprising ring moieties. In one aspect, embodiments are generally related to compositions that mimic naturally- occurring polyphenol compounds. The compositions comprise, in some embodiments, a polymer backbone having a plurality of hydroxyaromatic pendant side groups or derivatives thereof. For example, in some cases, a pendant side group may be a phenol or a substituted derivative thereof. In some cases, the pendant side group may be an oxidized hydroxyaromatic group, such as a quinone. In some embodiments, self-assembled structures comprising one or more of the polymer conjugates are provided. For example, the polymer conjugates may be combined with a complexing agent to form a particle. In some cases, a polymer conjugate may form a hydrogel. In some embodiments, the self-assembled structures may contain an agent, such as a pharmaceutically active agent. Also provided are methods and kits for forming the compositions, methods of using the compositions, and the like.
Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Lung Cancer Cohort participants will have locally advanced or metastatic lung cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.
Individuals with no known disease and normal urinalysis. Age ranging from 18 to 80 years old. Women of childbearing age should have negative urine pregnancy test.
Abstract Introduction: This study aimed to develop a scale to assess attitudes toward the use of telemedicine services, to study the reliability and validity of the developed scale, and to determine the characteristics that may be associated with the scores obtained from the scale. Methods: This study, which was conducted with 600 people older than 18 years, who applied to Family Health Centers in Meram district of Konya province, was designed in a methodological type. The sociodemographic characteristics form and the candidate scale form designed in a 5-point Likert structure were used to collect data in the study. The data collection forms were applied to the participants under observation. SPSS and R programs were used for data analysis. Statistically, cases with p < 0.05 were considered significant. Results: Two hundred fifty people (n = 250) for reliability and explanatory factor analysis and 350 people for confirmatory factor analysis, 600 people in total, were included in the study. The results of all reliability and validity analyses of the candidate scale were found to be sufficient. The explained variance of the one-dimensional 18-item scale was 53.8% and the Cronbach's alpha coefficient was 0.947. There was a significant difference between the score obtained from the scale and work status and presence of chronic disease (p < 0.05). Conclusion: As a result of the research, a new measurement tool called "Attitude Scale Towards the Use of Telemedicine Services" consisting of 18 questions was developed, reliability and validity analyses were performed, and it was shown that it is suitable for use in individuals older than 18 years.
Patients receive sorafenib tosylate PO QD or BID on days 1-28 and tipifarnib PO QD or BID on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients may be allowed to continue the treatment after the 12 courses if there is continued clinical response or disease stabilization, and patients do not have significant toxicities.
PURPOSE:The titled remedy, containing 5-methylallantoin as an active constituent, and having a remedial effect on the peptic ulcer with low toxicity. CONSTITUTION:A remedy for peptic ulcer containing 5-methylallantoin of formulaIas an active constituent. The active constituent of formulaIis synthesized by reacting a urea compd. of formula II with an alpha-ketocarboxylic acid of formula III in the presence of a dehydrating agent, preferably an acidic catalyst at room temperature or under a little warming. An inorganic acid, e.g. hydrochloric or sulfuric acid, is used as the acidic catalyst. The melting point, etc. of the 5-methylallantoin of formulaIare not described in literature, and the structure thereof is determined by elementary analyses and measurement of various spectra with the estimated 211 deg.C melting point. In use as the titled remedy, the dosage form for the oral administration is a tablet, capsule, powder, etc. may be cited, and the daily dose of the active constituent is suitably 100mg-1g for an adult.
Participants receive their first rapid infusion of isatuximab IV over 30 minutes. If a \>=Grade 2 iRR occurs, then participants will revert to a SOC infusion time and be removed from the study. If a Grade 1 or no IRR occurs, then participants will receive another rapid infusion of 30 minutes. Participants will continue to receive RI and IRR assessment after each dose up to at least 6 doses or until a grade 2 or higher IRR occurs.
PURPOSE:To provide the new compound exhibiting a low toxicity and useful, e.g. as an antipsychotic agent, an antianxiety agent and a medicine for improving cerebral functions. CONSTITUTION:A compound of formula I [W is H or a lower alkyl ; Y is a lower alkyl; Ar is a (hetero)aryl; R is H or a lower alkyl; R1 is H, a (cyclo) alkyl, a hydroxy(lower)alkyl, etc.; R2 and R3 are each H, a halogen, a lower alkyl, a lower alkoxy, hydroxy, trifluoromethyl, cyano, nitro or amino; R7 and R8 are each H or a lower alkyl; m is 2 or 3], e.g. 2-(4-ethyl-1-piperazinyl)--4-(4- fluorophenyl)-5,6-dimethylpyridine. In addition, the compound of formula I can be obtained by reacting a compound of formula II (X is an eliminable group) with a compound of formula III in the presence of a base such as triethylamine in a solvent such as toluene.
The duration of the study will be 22 days. Subjects will use a cream with a mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor on one cheek, and a cream lacking the inhibitor (vehicle control) on the other. Patients will receive a randomized set of creams for the right and left cheek, one containing the active ingredient. Subjects will be evaluated on days 1, 8, 15 and 22. Skin appearance will be scored in each visit. A blood sample will be obtained to determine the levels of systemic drug absorption.
A preparation method of lacidipine tablets. It relates to the technical field of medicine. The lacidipine tablet provided by the invention is prepared from lacidipine as a raw material and povidone, lactose monohydrate, dried lactose and magnesium stearate as auxiliary materials, and aims to solve the problems that the existing lacidipine tablet for a hypertension preparation is prepared by micronization of many lasidipes, is not shaded, and has poor taste, slow dissolution rate and low accumulative dissolution rate. The preparation method comprises the following steps: firstly, sieving; secondly, weighing raw and auxiliary materials; thirdly, preparation; fourthly, preparing solid in a dispersing way; fifthly, uniformly mixing the dispersoid and auxiliary materials; sixthly, direct tabletting; and seventhly, coating to obtain the coating. The lacidipine tablets are prepared by solid dispersion, the content is uniform, the coating is light-resistant and stable, the dissolution speed is high, and the accumulative dissolution rate is high. The invention is applied to the field of drug synthesis.
Registered patients will undergo a baseline FDG PET scan up to 14 days before administration of a single dose of the 89Zr-DFO-huJ591 tracer, this scan is considered for research purposes. The exception to the 14-day timeframe is that patients who have already had an FDG PET scan up to 4 weeks prior to registration are not required to repeat the FDG PET scan on study.
An important hallmark of glioblastoma aggressiveness is its altered metabolism of glucose. This metabolic shift wherein the tumor cells employ aerobic glycolysis regardless of oxygen availability via reprogramming of mitochondrial oxidative phosphorylation is known as the Warburg effect. Previous literatures have linked this metabolic reprograming to tumor progression and glioblastoma cell proliferation making it a key target for targeted drug therapy. Based on this lacuna, the current study aimed to explore the therapeutic efficacy of the triple-drug combination of temozolomide, metformin and epigallocatechin gallate in attenuating Warburg effect and glucose uptake in glioblastoma both in vitro and in vivo. Our results showed that the triple-drug combination had significantly reduced glucose uptake and reversed the Warburg effect in glioblastoma cells and in the glioma-induced xenograft rat model. Thus, the triple-drug combination would serve as an effective therapeutic regime to hamper glioblastoma progression via altering glucose metabolism and improving the overall prognosis in patient setting.
AIM: To evaluate the impact of aldosterone excess on renal function in individuals with primary aldosteronism and to compare its evolution after surgery or mineralocorticoid receptor antagonist (MRA) treatment.
METHODS: A multicentre, retrospective cohort study of primary aldosteronism patients in follow-up in 36 Spanish tertiary hospitals, who underwent specific treatment for primary aldosteronism (MRA or adrenalectomy).
RESULTS: A total of 789 patients with primary aldosteronism were included, with a median age of 57.5 years and 41.8% being women. At primary aldosteronism diagnosis, the prevalence of chronic kidney disease (CKD) was 10.7% ( n  = 84), with 75% of cases classified as state 3a ( n  = 63). Primary aldosteronism patients with CKD had a longer duration of hypertension, a higher prevalence of type 2 diabetes, dyslipidaemia, cardiovascular events, hypokalaemia, and albuminuria. Unilateral adrenalectomy was performed in 41.8% of cases ( n  = 330), and 459 patients were treated with MRA. After a median follow-up of 30.7 months (range 13.3-68.4), there was a significant decline in the estimated glomerular filtration rate (eGFR) in operated patients and those receiving MRA. During follow-up, 24.4% of patients with CKD at the time of primary aldosteronism diagnosis had normalized renal function, and 39% of those with albuminuria had albuminuria remission. There were no differences in renal function or albuminuria regression between the two therapy groups. However, development of albuminuria was less common in operated than in medically treated patients (0 vs. 6.0%, P  = 0.009).
CONCLUSION: CKD affects around 10% of the patients with primary aldosteronism, with a higher risk in individuals with long-term hypertension, type 2 diabetes, dyslipidaemia, cardiovascular events, hypokalaemia, and albuminuria. At short-term, both MRA and surgical treatment lead to a reduction of renal function, but adrenalectomy led to higher renal protection.
The efficacy of NEXPLANON does not depend on daily, weekly, or monthly administration.

All healthcare professionals should receive instruction and training prior to performing insertion and/or removal of NEXPLANON.

A single NEXPLANON implant is inserted subdermally just under the skin at the inner side of the non-dominant upper arm. The insertion site is overlying the triceps muscle about 8-10 cm (3-4 inches) from the medial epicondyle of the humerus and 3-5 cm (1.25-2 inches) posterior to (below) the sulcus (groove) between the biceps and triceps muscles. This location is intended to avoid the large blood vessels and nerves lying within and surrounding the sulcus (see Figures 2a, 2b and 2c). Inserting an implant more deeply than subdermally (a deep insertion) may preclude palpation and localization, making removal difficult or impossible [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)]. 

NEXPLANON must be inserted by the expiration date stated on the packaging. NEXPLANON is a long-acting (up to 3 years), reversible, hormonal contraceptive method. The implant must be removed by the end of the third year and may be replaced by a new implant at the time of removal, if continued contraceptive protection is desired.
PURPOSE: Mebos, a traditional South Africa confection consisting of dried, pulped, and sugared apricots, is rich in fibre and vitamins, but also contains salicylic acid, flavonoids, and citric acid. We report a case of postoperative surgical site bleeding in a healthy patient who consumed approximately 2 kg of mebos per day prior to his elective spinal surgery.
METHODS: The clinical course of a previously healthy 54-year-old male patient with cauda equina syndrome secondary to lumbar spinal stenosis who underwent surgical intervention with subsequent bleeding into the surgical site is discussed. The cause was investigated through biochemical analysis, thromboelastometry (ROTEM®) and mass and absorption spectrometry were applied to assess flavonoid, citric acid, and salicylic acid content.
RESULTS: ROTEM® revealed an abnormal clotting profile with an increased clot forming time, suggesting intrinsic coagulopathy. Mass and absorption spectrometry revealed a high total flavonoid content as well as citric acid concentration in the mebos. Salicylic acid was at detection limits of the instrument.
CONCLUSION: Results highlighted the effect of flavonoids and citric acid and therefore explain the abnormal clotting profile in this patient. Inhibition of coagulation prior to elective surgery is a known contraindication and may pose great risks in spinal surgery. In the present report, we demonstrated an association between inhibition of coagulation and an excess of the flavonoids content and citric acid concentration in mebos consumed in the days prior to elective spinal surgery.
Phenylcyclobutylamide derivatives and their optical isomers, the preparing processes and the uses thereof, which includes the compounds of formula (I), their pure stereoisomers and their pharmaceutically acceptable salts. In formula (I), R is H, formacyl, acetyl, haloacetyl, benzoyl, benzyloxy carbonyl (Cbz), t-butoxy carbonyl (Boc), or 9-fluorenyl methoxyl carbonyl (Fmoc). The present novel compounds have pharmaceutical activity and are prepared by condensation reaction of racemic, levo- or dextro- demethyl Sibutramine and racemic or D/L isoleucine under a mild condition. It is demonstrated that the present compounds have effect of losing weight to obese mode rats in different level and the effect is better than Sibutramine by the animal experiments. So the medicaments prepared by the present compounds or the medicaments prepared by the compositions of the present compounds and other pharmaceutical activity compounds may be used for treating obesity. (see formula I)
The Public Health System of Andalusia develops the Socio-Educational Groups Strategy (GRUSE), focused on promoting the health and emotional well-being of those who present somatic symptoms without organic cause in primary care health centers. This intervention began with groups of women and has been extended to groups of men, after verifying that the unemployment caused by the economic crisis, generated discomfort due to the loss of the "productive role". A mixed methodology research has been designed to measure the effects of GRUSE in male participants. The quantitative design has longitudinal and quasi-experimental section, in which a battery of scales are used as instruments for collecting information. The qualitative design includes semi-structured interviews and focus groups. The objective of this article is to present the design of the research, with which it is expected to collect evidence of the impact of the intervention.